DLC-50
DLC-50 is a dual inhibitor for PARP-1 and HDAC-1 with IC50 of 1.2 nM and 31 nM. DLC-50 inhibits the proliferation of cancer cells MDA-MB-436, MDA-MB-231, and MCF-7 with IC50 of 0.3, 2.7 and 2.41 μM. DLC-50 induces apoptosis in MDA-MB-231, arrests the cell cycle at G2 phase[1].
Product Specifications
CAS Number
2928537-98-6
UNSPSC
12352005
Target
Apoptosis; HDAC; PARP
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/dlc-50.html
Smiles
O=C1NN=C(CC2=CC=C(F)C(C(N3CCN(C(SCCCCCCC(NO)=O)=S)CC3)=O)=C2)C4=CC=CC=C41
Molecular Formula
C28H32FN5O4S2
Molecular Weight
585.71
References & Citations
[1]Wu J, et al. Design, synthesis and antitumor activities of phthalazinone derivatives as PARP-1 inhibitors and PARP-1/HDAC-1 inhibitors[J]. Bioorganic Chemistry, 2024: 107556.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HDAC1; PARP1
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog